A Phase 1/2 interventional study of MAR001 and Placebo in Hypertriglyceridemia, sponsored by Marea Therapeutics. Completed at 2 sites in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-13.
Sponsored by Marea Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hypertriglyceridemia with a site in Australia — 3 open to participants now, 6 under way, 2 of them phase 3. Hypertriglyceridemia · Australia.
Among the 15 studies in Hypertriglyceridemia with a site in Australia, this one is the 14th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 1/2, and was the 8th registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →3 of the 15 studies in Hypertriglyceridemia with a site in Australia are open now. Recruiting first, the newest first:
Marea Therapeutics · Sites in Australia, United States, Canada and 1 more country
Ages 18–75
Verve Therapeutics, Inc. · Sites in Australia, United States, Canada and 3 more countries
Ages 18–70
CRISPR Therapeutics AG · Sites in Australia, United States, New Zealand and 1 more country
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 6
First in 2011; this study’s year is marked. 1 started in 2023.
This study's enrollment of 55 is below the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 229 across the 15 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 8 most frequent:
Marea Therapeutics is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Marea Therapeutics has 3 studies filed under Hypertriglyceridemia — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypertriglyceridemia with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681351Phase 3Ionis Pharmaceuticals, Inc.CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | 2027-03 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
| NCT07028749Marea TherapeuticsStudy of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Hypertriglyceridemia with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: additional inclusion/exclusion criteria may apply, per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection
Drug: MAR001
Subcutaneous injection
Drug: Placebo
Subcutaneous injection
Subcutaneous injection
Safety and tolerability of MAR001
Incidence and frequency of treatment-emergent adverse events
Time frame: 12 weeks
Effect of MAR001 on triglyceride metabolism
Change from baseline in triglyceride levels
Time frame: 12 weeks
Ran from Jul 2023 to primary completion in Dec 2024, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MAR001
Marea Therapeutics